SCLERODERMA FIBROBLASTS SUPPRESS ANGIOGENESIS VIA TGF-beta/CAVEOLIN-DEPENDENT SECRETION OF PIGMENTED EPITHELIUM DERIVED FACTOR: TGF-beta RECEPTOR INHIBITORS AS A NOVEL THERAPEUTIC TARGET FOR THE TREATMENT OF SCLERODERMA
J Elies, F. Galdo(Complexo Hospitalario Universitario A Coruña), Roberto Giacomelli(Policlinico Umberto I), Patrick Emery(University of Massachusetts Chan Medical School), CP Denton(The Royal Free Hospital), Vasiliki Liakouli, Giuseppina Abignano(NIHR Leeds Musculoskeletal Biomedical Research Unit), Filomena Esteves, Georgia Mavria
White Rose Research Online (University of Leeds, The University of Sheffield, University of York)
August 1, 2017
Cited by 0
Related Papers
Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach
|Annals of the Rheumatic Diseases|2003|769
White Matter Lesions in an Unselected Cohort of the Elderly
|Stroke|2006|590
Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial
|Annals of the Rheumatic Diseases|2010|503
Open-Label Trial of Anti-TNF-α in Dermato- and Polymyositis Treated Concomitantly with Methotrexate
|European Neurology|2008|99
Submaximal exercise testing in the assessment of interstitial lung disease secondary to systemic sclerosis: reproducibility and correlations of the 6-min walk test
|Annals of the Rheumatic Diseases|2006|98